Pharmacologic treatments for pediatric bipolar disorder: A review and meta-analysis

Howard Y Liu, Mona P. Potter, K. Yvonne Woodworth, Dayna M. Yorks, Carter R. Petty, Janet R. Wozniak, Stephen V. Faraone, Joseph Biederman

Research output: Contribution to journalReview article

73 Citations (Scopus)

Abstract

Objective: A growing body of literature has documented pediatric bipolar disorder to be a severely impairing form of psychopathology. However, concerns remain as to the inadequacy of the extant literature on its pharmacotherapy. Furthermore, treatment studies have not been systematically reviewed for treatment effects on core and associated symptoms. Thus, a systematic evaluation and synthesis of the available literature on the efficacy of antimanic pharmacotherapy for pediatric bipolar disorder on symptoms of mania, depression, and attention-deficit/hyperactivity disorder was undertaken. Method: A systematic search was conducted through PubMed from 1989 through 2010 for open-label and randomized controlled trials published in English on the pharmacotherapy of pediatric mania. Results: There have been 46 open-label (n = 29) and randomized (n = 17) clinical trials of antimanic agents in pediatric bipolar disorder encompassing 2,666 subjects that evaluated a range of therapeutic agents, including traditional mood stabilizers, other anticonvulsants, second-generation antipsychotics, and naturopathic compounds. This literature has documented that the available armamentarium has different levels of efficacy in the treatment of pediatric mania. Because all psychotropic classes are associated with important adverse effects, a careful risk-benefit analysis is warranted when initiating pharmacologic treatment with any of these compounds. In the limited data available, the effects of antimanic agents on depression and symptoms of attention-deficit/hyperactivity disorder have been, in general, modest. Few studies have evaluated the effects of antimanic agents in children younger than 10 years. Conclusions: A substantial body of scientific literature has evaluated the safety and efficacy of various medicines and drug classes in the treatment of mania in pediatric bipolar disorder. More work is needed to assess the safety and efficacy of psychotropic drugs in children younger than 10 years, to further evaluate the efficacy of naturopathic compounds, and to further evaluate the effects of antimanic treatments for the management of depression and attention-deficit/hyperactivity disorder.

Original languageEnglish (US)
Pages (from-to)749-762.e39
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume50
Issue number8
DOIs
StatePublished - Aug 2011

Fingerprint

Bipolar Disorder
Antimanic Agents
Meta-Analysis
Pediatrics
Attention Deficit Disorder with Hyperactivity
Therapeutics
Depression
Drug Therapy
Literature
Safety
Psychotropic Drugs
Psychopathology
PubMed
Anticonvulsants
Antipsychotic Agents
Randomized Controlled Trials
Clinical Trials
Pharmaceutical Preparations

Keywords

  • attention-deficit/hyperactivity disorder
  • depression
  • mania
  • pediatric bipolar disorder
  • psychopharmacology

ASJC Scopus subject areas

  • Developmental and Educational Psychology
  • Psychiatry and Mental health

Cite this

Pharmacologic treatments for pediatric bipolar disorder : A review and meta-analysis. / Liu, Howard Y; Potter, Mona P.; Woodworth, K. Yvonne; Yorks, Dayna M.; Petty, Carter R.; Wozniak, Janet R.; Faraone, Stephen V.; Biederman, Joseph.

In: Journal of the American Academy of Child and Adolescent Psychiatry, Vol. 50, No. 8, 08.2011, p. 749-762.e39.

Research output: Contribution to journalReview article

Liu, HY, Potter, MP, Woodworth, KY, Yorks, DM, Petty, CR, Wozniak, JR, Faraone, SV & Biederman, J 2011, 'Pharmacologic treatments for pediatric bipolar disorder: A review and meta-analysis', Journal of the American Academy of Child and Adolescent Psychiatry, vol. 50, no. 8, pp. 749-762.e39. https://doi.org/10.1016/j.jaac.2011.05.011
Liu, Howard Y ; Potter, Mona P. ; Woodworth, K. Yvonne ; Yorks, Dayna M. ; Petty, Carter R. ; Wozniak, Janet R. ; Faraone, Stephen V. ; Biederman, Joseph. / Pharmacologic treatments for pediatric bipolar disorder : A review and meta-analysis. In: Journal of the American Academy of Child and Adolescent Psychiatry. 2011 ; Vol. 50, No. 8. pp. 749-762.e39.
@article{4fad60c6f936485f92001a7a2f822fa9,
title = "Pharmacologic treatments for pediatric bipolar disorder: A review and meta-analysis",
abstract = "Objective: A growing body of literature has documented pediatric bipolar disorder to be a severely impairing form of psychopathology. However, concerns remain as to the inadequacy of the extant literature on its pharmacotherapy. Furthermore, treatment studies have not been systematically reviewed for treatment effects on core and associated symptoms. Thus, a systematic evaluation and synthesis of the available literature on the efficacy of antimanic pharmacotherapy for pediatric bipolar disorder on symptoms of mania, depression, and attention-deficit/hyperactivity disorder was undertaken. Method: A systematic search was conducted through PubMed from 1989 through 2010 for open-label and randomized controlled trials published in English on the pharmacotherapy of pediatric mania. Results: There have been 46 open-label (n = 29) and randomized (n = 17) clinical trials of antimanic agents in pediatric bipolar disorder encompassing 2,666 subjects that evaluated a range of therapeutic agents, including traditional mood stabilizers, other anticonvulsants, second-generation antipsychotics, and naturopathic compounds. This literature has documented that the available armamentarium has different levels of efficacy in the treatment of pediatric mania. Because all psychotropic classes are associated with important adverse effects, a careful risk-benefit analysis is warranted when initiating pharmacologic treatment with any of these compounds. In the limited data available, the effects of antimanic agents on depression and symptoms of attention-deficit/hyperactivity disorder have been, in general, modest. Few studies have evaluated the effects of antimanic agents in children younger than 10 years. Conclusions: A substantial body of scientific literature has evaluated the safety and efficacy of various medicines and drug classes in the treatment of mania in pediatric bipolar disorder. More work is needed to assess the safety and efficacy of psychotropic drugs in children younger than 10 years, to further evaluate the efficacy of naturopathic compounds, and to further evaluate the effects of antimanic treatments for the management of depression and attention-deficit/hyperactivity disorder.",
keywords = "attention-deficit/hyperactivity disorder, depression, mania, pediatric bipolar disorder, psychopharmacology",
author = "Liu, {Howard Y} and Potter, {Mona P.} and Woodworth, {K. Yvonne} and Yorks, {Dayna M.} and Petty, {Carter R.} and Wozniak, {Janet R.} and Faraone, {Stephen V.} and Joseph Biederman",
year = "2011",
month = "8",
doi = "10.1016/j.jaac.2011.05.011",
language = "English (US)",
volume = "50",
pages = "749--762.e39",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "8",

}

TY - JOUR

T1 - Pharmacologic treatments for pediatric bipolar disorder

T2 - A review and meta-analysis

AU - Liu, Howard Y

AU - Potter, Mona P.

AU - Woodworth, K. Yvonne

AU - Yorks, Dayna M.

AU - Petty, Carter R.

AU - Wozniak, Janet R.

AU - Faraone, Stephen V.

AU - Biederman, Joseph

PY - 2011/8

Y1 - 2011/8

N2 - Objective: A growing body of literature has documented pediatric bipolar disorder to be a severely impairing form of psychopathology. However, concerns remain as to the inadequacy of the extant literature on its pharmacotherapy. Furthermore, treatment studies have not been systematically reviewed for treatment effects on core and associated symptoms. Thus, a systematic evaluation and synthesis of the available literature on the efficacy of antimanic pharmacotherapy for pediatric bipolar disorder on symptoms of mania, depression, and attention-deficit/hyperactivity disorder was undertaken. Method: A systematic search was conducted through PubMed from 1989 through 2010 for open-label and randomized controlled trials published in English on the pharmacotherapy of pediatric mania. Results: There have been 46 open-label (n = 29) and randomized (n = 17) clinical trials of antimanic agents in pediatric bipolar disorder encompassing 2,666 subjects that evaluated a range of therapeutic agents, including traditional mood stabilizers, other anticonvulsants, second-generation antipsychotics, and naturopathic compounds. This literature has documented that the available armamentarium has different levels of efficacy in the treatment of pediatric mania. Because all psychotropic classes are associated with important adverse effects, a careful risk-benefit analysis is warranted when initiating pharmacologic treatment with any of these compounds. In the limited data available, the effects of antimanic agents on depression and symptoms of attention-deficit/hyperactivity disorder have been, in general, modest. Few studies have evaluated the effects of antimanic agents in children younger than 10 years. Conclusions: A substantial body of scientific literature has evaluated the safety and efficacy of various medicines and drug classes in the treatment of mania in pediatric bipolar disorder. More work is needed to assess the safety and efficacy of psychotropic drugs in children younger than 10 years, to further evaluate the efficacy of naturopathic compounds, and to further evaluate the effects of antimanic treatments for the management of depression and attention-deficit/hyperactivity disorder.

AB - Objective: A growing body of literature has documented pediatric bipolar disorder to be a severely impairing form of psychopathology. However, concerns remain as to the inadequacy of the extant literature on its pharmacotherapy. Furthermore, treatment studies have not been systematically reviewed for treatment effects on core and associated symptoms. Thus, a systematic evaluation and synthesis of the available literature on the efficacy of antimanic pharmacotherapy for pediatric bipolar disorder on symptoms of mania, depression, and attention-deficit/hyperactivity disorder was undertaken. Method: A systematic search was conducted through PubMed from 1989 through 2010 for open-label and randomized controlled trials published in English on the pharmacotherapy of pediatric mania. Results: There have been 46 open-label (n = 29) and randomized (n = 17) clinical trials of antimanic agents in pediatric bipolar disorder encompassing 2,666 subjects that evaluated a range of therapeutic agents, including traditional mood stabilizers, other anticonvulsants, second-generation antipsychotics, and naturopathic compounds. This literature has documented that the available armamentarium has different levels of efficacy in the treatment of pediatric mania. Because all psychotropic classes are associated with important adverse effects, a careful risk-benefit analysis is warranted when initiating pharmacologic treatment with any of these compounds. In the limited data available, the effects of antimanic agents on depression and symptoms of attention-deficit/hyperactivity disorder have been, in general, modest. Few studies have evaluated the effects of antimanic agents in children younger than 10 years. Conclusions: A substantial body of scientific literature has evaluated the safety and efficacy of various medicines and drug classes in the treatment of mania in pediatric bipolar disorder. More work is needed to assess the safety and efficacy of psychotropic drugs in children younger than 10 years, to further evaluate the efficacy of naturopathic compounds, and to further evaluate the effects of antimanic treatments for the management of depression and attention-deficit/hyperactivity disorder.

KW - attention-deficit/hyperactivity disorder

KW - depression

KW - mania

KW - pediatric bipolar disorder

KW - psychopharmacology

UR - http://www.scopus.com/inward/record.url?scp=79960835197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960835197&partnerID=8YFLogxK

U2 - 10.1016/j.jaac.2011.05.011

DO - 10.1016/j.jaac.2011.05.011

M3 - Review article

C2 - 21784295

AN - SCOPUS:79960835197

VL - 50

SP - 749-762.e39

JO - Journal of the American Academy of Child and Adolescent Psychiatry

JF - Journal of the American Academy of Child and Adolescent Psychiatry

SN - 0890-8567

IS - 8

ER -